Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Hormone Replacement Therapy | Research

Exogenous hormone therapy and non-melanoma skin cancer (keratinocyte carcinoma) risk in women: a systematic review and meta-analysis

Authors: Lin Li, Baoqiang Pei, Yanyan Feng

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Previous studies reported inconsistent results regarding the association between keratinocyte carcinoma (KC) and exogenous hormone therapy. This study aimed to investigate the association between the use of exogenous sex hormones and the risk of KC among women. The databases of PubMed, Ovid Medline, Cochrane, and Web of Science were searched until May 2023. A total of 5293 patients with KC and 106,424 controls were included for analysis. The meta-analysis indicated that oral contraceptives (OC) and hormonal replacement therapy (HRT) use were associated with an increased risk of squamous cell carcinoma (SCC) (OR/RR = 1.25, 95% CI 1.10 to 1.43, I2 = 41.6%, p = 0.080). Subgroup analysis showed that OC use increased the risk of SCC (OR/RR = 1.37, 95% CI 1.15 to 1.63), whereas no significant association was shown between HRT use and risk of SCC (OR/RR = 1.13, 95% CI 0.93 to 1.37). Additionally, OC and HRT use were linked to an increased risk of basal cell carcinoma (BCC) (OR/RR = 1.16, 95% CI 1.09 to 1.25, I2 = 30.1%, p = 0.188). Further subgroup analysis suggested both OC and HRT use were associated with an increased risk of BCC (OC: OR/RR = 1.13, 95% CI 1.01 to 1.25; HRT: OR/RR = 1.19, 95% CI 1.09 to 1.30). In conclusion, our findings support the hypothesis that the risk of KC among women may be affected by the use of exogenous hormones.
Appendix
Available only for authorised users
Literature
1.
Tang E, Fung K, Chan AW. Incidence and mortality rates of keratinocyte carcinoma from 1998–2017: a population-based study of sex differences in Ontario, Canada. CMAJ. 2021;193(39):E1516–24.CrossRefPubMedPubMedCentral
2.
Loney T, Paulo MS, Modenese A, Gobba F, Tenkate T, Whiteman DC, Green AC, John SM. Global evidence on occupational sun exposure and keratinocyte cancers: a systematic review. Br J Dermatol. 2021;184(2):208–18.CrossRefPubMed
3.
4.
Leiter U, Keim U, Garbe C. Epidemiology of skin Cancer: Update 2019. Adv Exp Med Biol. 2020;1268:123–39.CrossRefPubMed
5.
Garbe C, Keim U, Gandini S, Amaral T, Katalinic A, Hollezcek B, Martus P, Flatz L, Leiter U, Whiteman D. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036. Eur J Cancer. 2021;152:18–25.CrossRefPubMed
6.
Sella T, Goren I, Shalev V, Shapira H, Zandbank J, Rosenblum J, Kimlin MG, Chodick G. Incidence trends of keratinocytic skin cancers and melanoma in Israel 2006-11. Br J Dermatol. 2015;172(1):202–7.CrossRefPubMed
7.
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma skin Cancer (keratinocyte carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015;151(10):1081–6.CrossRefPubMed
8.
Kwiatkowska M, Ahmed S, Ardern-Jones M, Bhatti LA, Bleiker TO, Gavin A, Hussain S, Huws DW, Irvine L, Langan SM, et al. An updated report on the incidence and epidemiological trends of keratinocyte cancers in the United Kingdom 2013–2018. Skin Health Dis. 2021;1(4):e61.CrossRefPubMedPubMedCentral
9.
Josiah AJ, Twilley D, Pillai SK, Ray SS, Lall N. Pathogenesis of keratinocyte carcinomas and the therapeutic potential of Medicinal plants and phytochemicals. Molecules 2021, 26(7).
10.
Nagarajan P, Asgari MM, Green AC, Guhan SM, Arron ST, Proby CM, Rollison DE, Harwood CA, Toland AE. Keratinocyte carcinomas: current concepts and Future Research Priorities. Clin Cancer Res. 2019;25(8):2379–91.CrossRefPubMed
11.
Lee KJ, Soyer HP. Cutaneous keratinocyte cancers of the head and neck: Epidemiology, risk factors and clinical, dermoscopic and reflectance confocal microscopic features. Oral Oncol. 2019;98:109–17.CrossRefPubMed
12.
Kappelin J, Green AC, Ingvar Ã, Ahnlide I, Nielsen K. Incidence and trends of basal cell carcinoma in Sweden: a population-based registry study. Br J Dermatol. 2022;186(6):963–9.CrossRefPubMed
13.
Hogue L, Harvey VM. Basal cell carcinoma, squamous cell carcinoma, and cutaneous melanoma in skin of Color Patients. Dermatol Clin. 2019;37(4):519–26.CrossRefPubMed
14.
Abi Karam M, Kourie HR, Jalkh N, Mehawej C, Kesrouani C, Haddad FG, Feghaly I, Chouery E, Tomb R. Molecular profiling of basal cell carcinomas in young patients. BMC Med Genomics. 2021;14(1):187.CrossRefPubMedPubMedCentral
15.
Thomson J, Hogan S, Leonardi-Bee J, Williams HC, Bath-Hextall FJ. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020;11(11):Cd003412.PubMed
16.
Corchado-Cobos R, García-Sancha N, González-Sarmiento R, Pérez-Losada J, Cañueto J. Cutaneous squamous cell carcinoma: from Biology to Therapy. Int J Mol Sci 2020, 21(8).
17.
Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am. 2019;33(1):1–12.CrossRefPubMed
18.
Conz L, Mota BS, Bahamondes L, Teixeira Dória M, Françoise M, Derchain S, Rieira R, Sarian LO. Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2020;99(8):970–82.CrossRefPubMed
19.
Zhang GQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, Talibov M, Zhang J, Hawrylowicz CM, Lumsden MA, et al. Menopausal hormone therapy and women’s health: an umbrella review. PLoS Med. 2021;18(8):e1003731.CrossRefPubMedPubMedCentral
20.
Cahoon EK, Kitahara CM, Ntowe E, Bowen EM, Doody MM, Alexander BH, Lee T, Little MP, Linet MS, Freedman DM. Female estrogen-related factors and incidence of basal cell carcinoma in a Nationwide US Cohort. J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(34):4058–65.CrossRef
21.
Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Subramaniam P, Nagle CM, Green AC, Neale RE, Webb PM, Whiteman DC. Hormonal and reproductive factors and incidence of basal cell carcinoma and squamous cell carcinoma in a large, prospective cohort. J Am Acad Dermatol. 2018;78(3):615–618e612.CrossRefPubMed
22.
Kuklinski LF, Zens MS, Perry AE, Gossai A, Nelson HH, Karagas MR. Sex hormones and the risk of keratinocyte cancers among women in the United States: a population-based case-control study. Int J Cancer. 2016;139(2):300–9.CrossRefPubMedPubMedCentral
23.
Birch-Johansen F, Jensen A, Olesen AB, Christensen J, Tjønneland A, Kjær SK. Does hormone replacement therapy and use of oral contraceptives increase the risk of non-melanoma skin cancer? Cancer Causes & Control: CCC. 2012;23(2):379–88.CrossRefPubMed
24.
Langevin SM, Grandis JR, Taioli E. Female hormonal and reproductive factors and head and neck squamous cell carcinoma risk. Cancer Lett. 2011;310(2):216–21.CrossRefPubMedPubMedCentral
25.
Asgari MM, Efird JT, Warton EM, Friedman GD. Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case-control study. Int J Environ Res Public Health. 2010;7(2):427–42.CrossRefPubMedPubMedCentral
26.
Applebaum KM, Nelson HH, Zens MS, Stukel TA, Spencer SK, Karagas MR. Oral contraceptives: a risk factor for squamous cell carcinoma? J Invest Dermatol. 2009;129(12):2760–5.CrossRefPubMedPubMedCentral
27.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA Statement. Revista Española De Nutrición Humana Y Dietética 2009.
28.
Vessey MP, Painter R, Powell J. Skin disorders in relation to oral contraception and other factors, including age, social class, smoking and body mass index. Findings in a large cohort study. Br J Dermatol. 2000;143(4):815–20.CrossRefPubMed
29.
Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA repair and susceptibility to basal cell carcinoma: a case-control study. Am J Epidemiol. 1994;140(7):598–607.CrossRefPubMed
30.
Verdier-Sevrain S, Yaar M, Cantatore J, Traish A, Gilchrest BA. Estradiol induces proliferation of keratinocytes via a receptor mediated mechanism. Faseb j. 2004;18(11):1252–4.CrossRefPubMed
31.
Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents–DNA adducts and mutations. J Natl Cancer Inst Monogr. 2000;27:75–93.CrossRef
32.
Cooper SM, George S. Photosensitivity reaction associated with use of the combined oral contraceptive. Br J Dermatol. 2001;144(3):641–2.CrossRefPubMed
33.
Richarz NA, Aguilera J, Castillo G, Fuente MJ, Ferrándiz C, Carrascosa JM. Phototoxic reaction to a combined oral contraceptive (levonorgestrel/ethinylestradiol). Photochem Photobiol Sci. 2017;16(9):1381–3.CrossRefPubMed
34.
35.
Faust H, Andersson K, Luostarinen T, Gislefoss RE, Dillner J. Cutaneous human papillomaviruses and squamous cell carcinoma of the skin: nested case-control study. Cancer Epidemiol Biomarkers Prev. 2016;25(4):721–4.CrossRefPubMed
36.
Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018;31(4):461–5.CrossRefPubMed
37.
Kyle RG, Macmillan I, Forbat L, Neal RD, O’Carroll RE, Haw S, Hubbard G. Scottish adolescents’ sun-related behaviours, tanning attitudes and associations with skin cancer awareness: a cross-sectional study. BMJ Open. 2014;4(5):e005137.CrossRefPubMedPubMedCentral
38.
Lee A, Garbutcheon-Singh KB, Dixit S, Brown P, Smith SD. The influence of age and gender in knowledge, behaviors and attitudes towards sun protection: a cross-sectional survey of australian outpatient clinic attendees. Am J Clin Dermatol. 2015;16(1):47–54.CrossRefPubMed
39.
Caini S, De Angelis SP, Corso F, Fantini C, Raimondi S, Pala L, Stanganelli I, de Giorgi V, Gandini S. Exogenous sex hormones, menstrual and reproductive history, and risk of non-melanoma skin cancer among women: a systematic literature review and meta-analysis. Sci Rep. 2021;11(1):8524.CrossRefPubMedPubMedCentral
Metadata
Title
Exogenous hormone therapy and non-melanoma skin cancer (keratinocyte carcinoma) risk in women: a systematic review and meta-analysis
Authors
Lin Li
Baoqiang Pei
Yanyan Feng
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11459-0

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

Early prediction of response to palliative chemotherapy in patients with stage-IV gastric and esophageal cancer

Research

Prognostic significance of lymphovascular invasion in patients with pT1b esophageal squamous cell carcinoma

Research

MicroRNA-21 promotes head and neck squamous cell carcinoma (HNSCC) induced transition of bone marrow mesenchymal stem cells to cancer-associated fibroblasts

Research

Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Research

The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis

Research

Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: a multicenter study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits